PridCor Therapeutics funds Phase 2 Long COVID trial at Mount Sinai
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PridCor Therapeutics announced it made the first payment under its clinical trial agreement with the Icahn School of Medicine at Mount Sinai for the SHIELD Study. The study drug has been ordered in preparation for enrollment in the randomized, double-blind, placebo-controlled Phase 2 trial. SHIELD is designed to evaluate a combination antiviral regimen for approximately 150 adults with Long COVID.
From manilatimes.net
Why it matters
The funding supports the research and development of antiviral treatments for Long COVID. This activity relates to the operational costs of the Icahn School of Medicine at Mount Sinai and the clinical research pipeline of PridCor Therapeutics.
From manilatimes.net
Who's involved
- Icahn School of Medicine at Mount SinaiConducting the SHIELD clinical trial
- Mount Sinai Health SystemParent hospital network of the Icahn School of Medicine at Mount Sinai
- Mount SinaiLocation where the Icahn School of Medicine operates
- National Institutes of HealthProvides current funding and resources for research at the Icahn School of Medicine at Mount Sinai
- Kunal SindhuAssistant professor at the Icahn School of Medicine at Mount Sinai
Keep exploring
The entities involved
-
Icahn School of Medicine at Mount Sinai
medical school